Table 2.

Listing of therapies received by patients between sample procurements

CLL IDIntercurrent therapyClonal evolution (CE) or stability?
CLL002R → FCRCE (+aCNA)
CLL004FRstable
CLL007FRCE (+aCNA, −aCNA)
CLL008FRCE (+aCNA)
CLL010FRCE (+aCNA)
CLL011FRCE (+aCNA)
CLL013R-CVPStable
CLL017FR → FCRStable
CLL021R-CVPStable
CLL024FRCE (+aCNA)
CLL027FRStable
CLL029FRstable
CLL033FR → PCRCE (+aCNA)
CLL036FRCE (+cn-LOH)
CLL056RStable
CLL060PCRStable
CLL066R → PCRStable
CLL069R → RStable
CLL074FRCE (+aCNA)
CLL078FRStable
CLL084R → R+MP→OStable
CLL085FCRStable
CLL094A → BR → OStable
CLL104F → ACE (+aCNA, −aCNA)
CLL109FRStable
CLL112FRStable
CLL116FRCE (+cn-LOH)
CLL117FCR → BRCE (+aCNA, +TP53 mut, +cn-LOH, −NOTCH1 mut)
CLL120FRStable
CLL121FCRCE (+aCNA)
CLL125F → BCE (+TP53 mut)
CLL135FRStable
CLL155FCRStable
CLL170PCR → flavopiridol → RICEStable
CLL176FCRStable
CLL207R → RStable
CLL209PCRCE (+aCNA)
CLL212BRStable
CLL219R-CVP → BCE (+TP53 mut)
CLL239RCE (+aCNA)
CLL242F → FC → BRStable
CLL271BStable

Abbreviations: F, fludarabine; C, cyclophosphamide; R, rituximab; A, alemtuzumab; O, ofatumumab; V, vincristine; P, prednisone; P, pentostatin; M, methylprednisolone; I, ifosphamide; E, etoposide.